Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (October 2006)
25 slides from Biotron's shareholder meeting presentation, Oct 20, 2006
Slide 1: Presentation to Annual General Meeting (ASX cover letter)
BIOTCL OM timitea A.B.N, 60 086 399 144 Level 8, 261 George Street Sydney NSW 2000 Tel: (61-2) 9247 8212 Fax: (61-2) 9247 3932 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 20 October 2006 The Manager Companies Australian Stock Exchange Limited 20 Bridge Street SYDNEY NSW 2000 (25
Slide 2: AGM 20 October 2006
AGM 20 October 2006
Slide 3: sea seus passa
sea seus passa Fe a Le Do j oe 2 7 yo ay 7 - Le oo) ee LD i ee oe eg oe oe 7 / a ; y Le a fe Ce Le yy a : 7 ie e a its ; : / a ie yy ye ay ee yy IM oy: 7 Ly Le SIS ei — ee — ee RU SII OTR SEES IDES OFS ey USSG SUITS LL 7 >) CFC - ee as ae os ss oy, e Ee ete | a BS Bas ye Gage % i ye . Bh S eae ee Ye
Slide 4: : A a) Co
: A a) Co Lo ae C7 hl | . Ce as / lr C i: fy Dy Gin Oa ee Be KS iY ey eS ys ee ey a oe Gs ee a Lye. Cy ys ye a. Ly oe ] 7 Lo / es 0 LL Ly Le on OEE —- _ LEED _ _ is D _ . LESS _ LE De ag PR i Pe Bs S ee ne Ss Cll” 7 CrCl 0 7 Se Le Le a = he Cg) j 5 oy LE ee Lh Loy ee ey eo os q y y y ay Fae oo. | 7
Slide 5: HIV and HAART therapy
SS oS |. Po 4 — — — Fe on ee ‘ — — itable for HAART* therapy s US ID NCW Way a ce B oo S oO a coal = Me) o oO = = Oo e ~ that attack the v * ral Therapy Anti-Retroy Highly Active a
Slide 6: fo — — . oe al ce — ad compound to le as in
fo — — . oe al ce — ad compound to le as in cl a ae — ag) oO oO = oO o — oO Li i) o (ala, cl 2 3S | take to the cl In NIC ;
Slide 7: sop — eee _
sop — eee _ ee ee Vi : Cg : yy Le ee : J i ee y ] ay) ys oe i a a Yo pal ae 0 UL De De a en ye a es AG OY ey i Lo Ly) yy gy: ee) Lo y , y Le, a a) yee Ly, Le a i ey Lie f ee Lo a _ i __._6h6hChhehehesM a a 7 7 Bi . Lo ; a Ca : Z yy B y : i Ee LOTT ve y ee 7; 7 a es ee E ee , a, ay ae a Le on De _ |
Slide 8: BIT - Targets Different Stage
_ BIT- 225 TARGETS DIFFERENT Assembly & bugding Penetration gpi20 BIT compounds interrupt budding Attachmern
Slide 9: : - — oa
: - — oa
Slide 10: Oo =o... - ce — Cc — — a — — oo — PC
Oo =o... - ce — Cc — — a — — oo — PC
Slide 11: Novel compound and new mechanism
c So oo 10n s for manufactur f act 1Sm O Ss ic proce new mechan oo — seen oO s a ee shied: Soe c 2 a= 1ve Relati Novel compound Fa — oo
Slide 12: ae a i : : 7. Lo Lo _ | iy ae Be ae
ae a i : : 7. Lo Lo _ | iy ae Be ae a Lh Lo ye Ly a ae I ee Lee oF Ly oe LOG Ue Le Lo Le y : y ee g Vee | “~ vs Ts ie yy LL ae : - — a) yp Gee
Slide 13: a — — to — — OO = — oo : | oe Ic
a — — to — — OO = — oo : | oe Ic d tox Ive an ot 5) ao oO = Cael 1CS therapi ing t . 1S « Ex
Slide 14: iil
Ss iil g to | LFOPOE. lled v — —— INS Ca Ss 4 _— = a = a FH 3S ed oO £ os ea) prote =a ~ c
Slide 15: Preclinical data to fast-track to human trials
a oe — — -— — Se fo — — Re — . based on ials . an tr al to fast-track to hum | data generated : 1 : Potent in = E ft ob 2 a 2 = —_ = = = £ ica * preel
Slide 16: | — — oe a — - . — a Coe co, — o
| — — oe a — - . — a Coe 6 co, — o 3 E o 2 a 6 wo — o s 2 — fos 3 aS & IV. — Developing ting ~ Characte tes i {ant ing mode of action o TIS compounds
Slide 17: Diagnostics and other applications
oo a a -_- oe oe — ce ive assays Non-ivas 2. d rapi live, 1 -— Sens isorders -based d immune jabetes 3G = ° o a ce oD o onl E oO oO SS s 6. 6 2 “ Ja Potenti such as d *.
Slide 18: ’ 7A ny i > Ge eur ty PM ANON SL a
_ We — ce : a ’ 7A ny i > Ge eur ty PM ANON SL a d a is fy Low. Ee — igs a I LEI ; Y ye ay ae g Le. a Le 2 2 a. Vie : Le ce Lo a oS iy 77
Slide 19: : y y G oe LD LD ey j ay ee ne ue BEY
: 5 y y G oe LD LD ey j 7 7 ay ee ne ue BEY Ls 7 y a y 7 yeep i ey 2 Q a
Slide 20: os we oe wy open reesegaen
os we oe wy open reesegaen De LO D Ig Le 7 oe Ll. Le 7 | a LC ) 7 ie Um — . . — Les Me ie is CP I ESE NSA RTE Se, ee llr vy Wy, ye OU Ns Cl Lo LF — - Maye Bs TLS IED Se epee wee — Ce 7 ah Se Ly Ly
Slide 21: Dr Michelle Miller, Chief Executive Officer
Dr Michelle Miller Chief Executive Officer 02 6125 8001 mmiller@biotron.com.au www.biotron.com.au
Slide 22: Commentary for a Presentation to the 2006 AGM
= i] & ye =r Limited A.BN. 60 086 399 144 Level 8, 261 George Street Sydney NSW 2000 Tel: (61-2) 9247 8212 Fax: (61-2) 9247 3932 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au COMMENTARY FOR A PRESENTATION TO THE 2006 ANNUAL GENERAL MEETING 20 OCTOBER 2006 } am pleased to be able to
Slide 23: Commentary: BIT225 mechanism
Slide 6 BIT225 works at a different stage of the HIV life cycle compared to existing classes of HIV drugs. Existing drugs target one of three HIV proteins, as mentioned above, while BIT225 targets Vpu, a new drug target in the fight against HIV. BIT225 disrupts the budding, or the production and rel
Slide 24: Commentary: HCV program
Slide 11 The Virion antiviral technology has expanded to cover a wide range of economically significant viruses in addition to HIV-1. Whilst Biotron’s prime focus is on its anti-HIV drug development program, development of therapeutics for viruses other than HIV continue with a focus on HCV. HCV is
Slide 25: Commentary: C-Test cancer diagnostic update
Slide 15 C-Test - Cancer Diagnostic Update There is a real need for new tests that allow unambiguous cancer diagnoses to be made at an early stage. The best tests will be simple and non-invasive assays that allow rapid and accurate diagnosis of the type of cancer and its stage. While a number of tum